Introduction

Propylthiouracil is a thiocarbamide antithyroid agent used in Graves’ disease with hyperthyroidism and in toxic multinodular goitre.

It is a reserved second-line medicine carrying a boxed warning for severe liver injury, and our labelling carries that warning and the associated patient counselling text in full.

Complete CTD, ACTD and eCTD dossiers, in-vivo bioequivalence data, CoPP, FSC and ICH Zone IVb stability are supplied for MOH registration.

Product Overview Table

Field	Details
Product Name	Propylthiouracil Tablets
INN / Generic Name	Propylthiouracil
Therapeutic Class	Antithyroid agent thiocarbamide (thiourea derivative)
Mechanism (brief)	Inhibits thyroid hormone synthesis; also inhibits peripheral conversion of T4 to T3
Indications	Graves’ disease with hyperthyroidism and toxic multinodular goitre, in patients intolerant of methimazole and for whom surgery or radioactive iodine is not appropriate per approved local labelling
Positioning	Reserved second-line. Not first-line therapy.
Boxed Warning	Severe liver injury and acute liver failure, in some cases fatal, including cases requiring liver transplantation in adult and paediatric patients
Pregnancy Position	May be the treatment of choice when an antithyroid drug is indicated during or just prior to the First trimester, because of the risk of fetal abnormalities with methimazole. An alternative may be advisable after the first trimester.
Paediatric Use	Not recommended except in rare instances where methimazole is not tolerated and surgery or radioactive iodine are not appropriate
API Quality	Manufactured using DMF-grade Propylthiouracil
Pharmacopoeial Standard	USP Propylthiouracil Tablets USP; BP available
Available Strength	50 mg tablets
Reference Regimen	Total daily dose usually given in 3 divided doses. Initial 300 mg daily; maintenance typically 100-150 mg daily per approved labelling
Solubility Note	Very slightly soluble in water classification is borderline and must be established from your own data
Other Key Warning	Agranulocytosis in approximately 0.2% to 0.5% of patients, typically within the first three months of therapy
Shelf Life	36 Months
Storage	Store at 20-25°C, protect from light
Manufacturing Facility	WHO-GMP certified general oral solid dosage block, segregated from beta-lactam operations
Dossier Available	Yes, CTD / ACTD / eCTD format

Strength, Presentation & Specification

Propylthiouracil Tablets 50 mg

The single global strength. The total daily dose is usually given in three divided doses, with an initial dose of 300 mg daily and a usual maintenance dose in the range of 100 to 150 mg daily.

That arithmetic matters for anyone building a forecast: an initiation-phase patient takes six 50 mg tablets a day, dropping to two or three on maintenance.

Per-patient consumption is therefore substantially higher during the first weeks than the maintenance figure suggests, and a buyer who forecasts on maintenance dosing alone will under-order at exactly the wrong moment.

Specification & Testing

Assay, content uniformity, dissolution and related substances against the declared monograph

Discriminatory dissolution method validated across the physiological pH range the drug substance is very slightly soluble in water, so dissolution deserves genuine method development rather than a compliance-only approach

Photostability data supporting the light-protection storage statement

Taste and coating considerations: the drug substance has a markedly bitter taste, which is worth confirming is adequately managed in your formulation, particularly where the tablet may be split or crushed

Typical excipient system per reference labelling includes corn starch, docusate sodium, magnesium stearate and microcrystalline cellulose

Pharmacopoeial Compliance

USP Propylthiouracil Tablets USP is the specification most widely requested for export

BP / IP confirm applicability to your SKU before claiming compliance

Regulatory & Dossier Support

Dossier Availability

CTD (Common Technical Document) ICH-aligned, for regulated and semi-regulated markets

ACTD (ASEAN Common Technical Dossier) Philippines, Vietnam, Myanmar, Indonesia, Cambodia

eCTD for authorities mandating electronic submission

Module 3 quality documentation including process validation, dissolution method validation, content uniformity and photostability

Stability data real-time and accelerated under ICH Zone IVb (30°C / 75% RH)

Module 1 labelling built around the boxed warning and the patient counselling text on this molecule that is the primary risk control, not a formality.

Bioequivalence & Classification Position

Reference labelling describes propylthiouracil as a white crystalline substance that is very slightly soluble in water.

At a 50 mg strength, however, the dose-to-solubility ratio sits close to the boundary used in BCS classification, so whether a BCS-based biowaiver is available is a question to be settled from your own solubility data across the physiological pH range rather than assumed in either direction.

We recommend generating that data before choosing a registration route, because the answer changes the cost of every subsequent submission.

In-vivo bioequivalence (BE) data available

Where a biowaiver is pursued, the argument requires demonstrated solubility across the pH range plus rapid and comparable dissolution for both test and reference product

rather than relying on the general solubility description in reference labelling

Comparative dissolution profiles held throughout shelf life

Drug Master File (DMF)

Drug Master File (DMF) reference for the Propylthiouracil API available for cross-referencing in your registration dossier

API sourced against a qualified vendor with impurity, residual solvent, polymorph and particle size characterisation

CDSCO / Indian DMF reference accepted by a large number of importing authorities

Manufacturing Compliance

WHO-GMP certified manufacturing facility, audit-ready, with inspection reports shared on an NDA basis

Site Master File (SMF) available for regulatory submissions

Propylthiouracil is neither a beta-lactam nor a cytotoxic and is not subject to international drug control conventions, so no dedicated block is required.

Production runs in a general oral solid dosage block physically segregated from beta-lactam operations, with validated cleaning between products.

Small-batch capability is the relevant manufacturing question on this molecule.

Demand is low and stable rather than high and growing, so the practical constraint is whether campaigns can be run economically at modest scale without compromising validation

Compliant with the requirements of NAFDAC (Nigeria), PPB (Kenya), FDA Philippines, DRAP (Pakistan) and INVIMA (Colombia)

Complete Documentation Package (Per Shipment)

Document	Purpose
Certificate of Analysis (CoA)	Confirms batch quality against the agreed specification
Certificate of Pharmaceutical Product (CoPP / CPP)	Required for MOH registration in most importing countries
Free Sale Certificate (FSC)	Confirms the product is freely sold in the country of manufacture
Method of Analysis (MOA)	Analytical methodology mandatory dossier component
GMP Certificate	Confirms manufacturing site compliance
Stability Data	Real-time and accelerated ICH Zone IVb, plus photostability
BE Study Report or Biowaiver Justification	States explicitly which route was taken
Dissolution Profile Report	Across the physiological pH range
Content Uniformity Data	Batch-level
Approved Patient Leaflet, Translated	The primary risk control on this molecule
Excipient Declarations	For all inactive ingredients

Why the Leaflet Is the Safety Control Here

The practical consequence for an exporter is that leaflet quality on this product is not a printing decision.

Reference labelling directs that if patients develop tiredness, nausea, anorexia, fever, pharyngitis or malaise, propylthiouracil should be discontinued immediately by the patient, a physician contacted, and a white blood cell count, liver function tests and transaminase levels obtained.

A patient who cannot read or understand that sentence in their own language has lost the only protection the product offers.

Full boxed warning and patient counselling text carried in every leaflet, translated into the destination language and reviewed by a native speaker rather than machine-translated

Symptom list printed in plain language, not clinical terminology the instruction has to work for the patient, not for the prescriber

Agranulocytosis counselling included alongside the hepatic warning.

Agranulocytosis occurs in approximately 0.2% to 0.5% of patients and typically within the first three months of therapy, and the warning signs overlap with the hepatic ones fever and sore throat appear on both lists

Pregnancy text stated precisely. The first-trimester position and the advisability of switching to an alternative afterwards are both part of the labelling, and compressing them into a single sentence loses the timing distinction that matters clinically

We supply leaflet artwork proofs for regulatory review before printing, and we will not shorten safety text to fit a smaller leaflet format.

Where carton size is the constraint, the carton changes, not the warning

Clinical Indications, Positioning & Honest Market Assessment

Propylthiouracil is a thiocarbamide antithyroid agent. It inhibits the synthesis of thyroid hormone and additionally inhibits the peripheral conversion of T4 to T3.

Approved use: Graves’ disease with hyperthyroidism, and toxic multinodular goitre, in patients who are intolerant of methimazole and for whom surgery or radioactive iodine therapy is not an appropriate option per approved local labelling

Boxed warning: severe liver injury and acute liver failure, in some cases fatal, have been reported, including cases requiring liver transplantation in adult and paediatric patients.

Propylthiouracil should be reserved for patients who cannot tolerate methimazole and in whom radioactive iodine therapy or surgery are not appropriate.

The pregnancy position is the reason this molecule remains essential.

Because of the risk of fetal abnormalities associated with methimazole, propylthiouracil may be the treatment of choice when an antithyroid drug is indicated during or just prior to the first trimester of pregnancy.

After the first trimester, use of an alternative antithyroid medication may be advisable, given the potential for maternal hepatotoxicity.

Not recommended in paediatric patients except in rare instances where methimazole is not well tolerated and surgery or radioactive iodine are not appropriate

Agranulocytosis occurs in approximately 0.2% to 0.5% of patients and is a potentially life-threatening effect, typically arising within the first three months of therapy

Market Assessment Write This Honestly

The commercial shape of this product is unusual and worth stating plainly to the sales team.

Because propylthiouracil is formally reserved to second line, volumes in any market are small and have been declining as methimazole consolidated as first-line therapy.

A supplier who forecasts growth on this molecule will be wrong. But volumes cannot fall to zero, because the first-trimester pregnancy position leaves a defined group of patients for whom there is no substitute and that group exists in every market, every year, in numbers that track births rather than prescribing fashion.

Forecast small, flat and durable not growing, not disappearing

Continuity is worth more than price here. A pregnant patient in the first trimester with Graves’ disease has no alternative to fall back on, so a stockout on this product is a clinical problem rather than a substitution inconvenience

The commercial win is being the supplier who will run a small batch reliably rather than the one quoting the lowest price on a large one. Position the relationship that way and expect it to last

Export Packaging & Supply Chain

Primary Packaging Options

Presentation	Packaging Options
Propylthiouracil Tablets 50 mg	Alu-Alu blister 10×10 and 3×10, light-protective, in mono-carton with full leaflet
Hospital pack	HDPE bottle of 100 with induction seal, for institutional dispensing
Initiation pack	Configuration reflecting the higher initiation-phase dosing, where a buyer prefers it

Two practical points on pack design.

First, leaflet size is a constraint that has to be solved in favour of the safety text the boxed warning and the patient counselling content.

Second, initiation dosing consumes six tablets daily against two or three on maintenance, so a single pack size serves the two phases very differently; buyers running obstetric or endocrinology services may prefer a configuration that matches the initiation phase.

Why Source Propylthiouracil Tablets From Us?

We Will Run the Small Batch: Demand on this molecule is low and stable. We schedule modest campaigns against committed forecasts rather than pushing buyers to over-order and carry expiry risk on a slow-moving line. On a reserved-use product, that willingness is the whole value proposition.

Leaflet Treated as a Safety Control, Not a Formality: Full boxed warning and patient counselling text, translated by native speakers, in plain language. Reference labelling states that laboratory monitoring is not expected to attenuate the risk of severe liver injury, which makes the leaflet the control that actually works.

Complete Dossier in CTD, ACTD and eCTD: Pre-compiled with regulatory query response support and country-specific customisation.

Honest Classification Position: Propylthiouracil sits near the BCS solubility boundary at this strength. We advise generating solubility data before choosing a registration route rather than assuming a biowaiver is or is not available.

Continuity Where It Cannot Be Substituted: A first-trimester patient with Graves’ disease has no alternative. We plan supply on that basis rather than on volume attractiveness.

WHO-GMP Certified Manufacturing: Segregated general oral solid facility with validated cleaning. GMP certificate and Site Master File (SMF) shared on request.

Frequently Asked Questions

Ready to Source Propylthiouracil Tablets FDF?

Share your target market and expected annual patient numbers, and our export team will respond with the applicable specification, registration route, leaflet and translation approach, pack options and pricing sized to real demand rather than to a minimum order.

If you are at technical evaluation stage, request the dissolution and stability summaries, the leaflet proof, and a sample CoA.